Company / Shareholders' Equity
CUMBERLAND PHARMACEUTICALS INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$24.9M
FY2025
5-year range
$22.9M / $42.8M
FY2021-FY2025
Trend
+8.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2025 after 8 years of decline, reaching $25M.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of -11.9%.
Declined from $30M to $25M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -11.8%
- 5-Year CAGR
- -11.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.9%, indicating a declining trend.
- In FY2025, shareholders' equity increased 8.9% year-over-year.
- Peak shareholders' equity was recorded in FY2016.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.9M | +8.9% |
| FY2024 | $22.9M | -22.8% |
| FY2023 | $29.6M | -18.4% |
| FY2022 | $36.3M | -15.3% |
| FY2021 | $42.8M | -8.9% |
| FY2020 | $47.0M | -8.1% |
| FY2019 | $51.1M | -8.5% |
| FY2018 | $55.8M | -12.9% |
| FY2017 | $64.1M | -12.5% |
| FY2016 | $73.2M | -4.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026